Global HIV Funding Crisis
Donor Funding for HIV Programs Drops Sharply, Threatening Global Progress and 2030 Goals
Anonymous
Key Points
1
In 2025, government HIV funding fell to $7.3 billion — an 18% drop and the largest annual decline in nearly two decades, with prevention funding in sub-Saharan Africa historically around 83% donor-dependent two years ago.
2
Despite the funding squeeze, the United States remained the dominant donor, providing about 74% of donor-government HIV funding in 2025 even as total donor funding declined to roughly $6.2 billion—a 25% year-over-year drop.
3
The UNAIDS/IAS outlook highlights a chilling gap: 1.2 million new HIV infections and 570,000 AIDS-related deaths in 2025, with 22% of people living with HIV still not in treatment; while new prevention medicines like lenacapavir show near 100% efficacy, about 20 million people need ARV-based prevention, yet generics could cost as little as $40 per person annually and remain unavailable in many low- and middle-income countries; Brazil was excluded from being listed as a country authorized to manufacture lower-cost generics.
4
European donors have fallen sharply over the past decade—EU funding down about 58% since 2011—while the United States’ share of funding rose as Europe’s contributions waned.
Global donor funding for HIV programs fell to $7.3 billion in 2025 — an 18% drop and the steepest single-year decline in nearly two decades, according to UNAIDS. Experts at the AIDS 2026 conference in Rio de Janeiro warn the cuts are reversing years of hard-won progress.
The United States remained the world's largest HIV donor, covering about 74% of all donor-government HIV spending. But total donor disbursements still fell to roughly $6.2 billion — a 25% year-over-year drop — the lowest level since 2007, according to STAT News.
Children Losing Treatment as PEPFAR Sites Shut Down
About 77,163 fewer children received PEPFAR-supported HIV treatment in 2025 than the year before — a 14.2% drop. That decline happened across 20 of 21 high-burden countries analyzed. South Africa saw the sharpest fall, with roughly 30,880 fewer children getting treatment, a 45% reduction in just one year.
Behind those numbers are real service losses. Some 1,714 HIV service sites were shuttered or disrupted. More than half of PEPFAR implementing partners lost at least one funding award. About 77% of partners said new U.S. policies forced them to restrict activities, according to CTV News. Shortages of condoms, PrEP medicines, and antiretrovirals followed.
1.2 Million New Infections and a Widening Treatment Gap
Despite the funding squeeze, the epidemic did not slow. There were 1.2 million new HIV infections and 570,000 AIDS-related deaths in 2025. About 22% of people living with HIV were still not in treatment — a gap that experts say will grow if funding keeps falling, according to France 24.
New prevention medicines offer real hope. Lenacapavir, an injectable drug given twice a year, shows nearly 100% efficacy. Generic versions could cost as little as $40 per person per year. But about 20 million people who need ARV-based prevention still cannot get it. Many low- and middle-income countries lack access to cheaper generics. Brazil was even excluded from the list of countries authorized to manufacture low-cost generic versions.
Europe's Decade-Long Retreat Left the U.S. Holding the Bill
The United States did not cut its HIV aid in isolation. European donors have been pulling back for years. EU funding dropped about 58% since 2011. As Europe's contributions shrank, the U.S. share of global HIV donor funding rose to fill the gap — reaching 74% by 2025, according to STAT News.
Now that the U.S. is also cutting back, there is no other donor large enough to absorb the loss. France, Germany, and the UK have not stepped up to replace what has been lost, CTV News reported. Sub-Saharan Africa, where about 83% of HIV prevention funding historically came from donors, faces the sharpest exposure to this shift.
Scientists and Activists Demand Action Before Epidemic Rebounds
Researchers at the Rio conference are calling the situation a turning point — in the wrong direction. They say the world had the tools and the knowledge to end AIDS by 2030. Now, that timeline is in doubt. The combination of funding cuts, site closures, and medicine shortages risks triggering a full resurgence of the epidemic.
Activists are urging governments to diversify HIV financing and commit new money fast. They point to lenacapavir's near-perfect efficacy as proof that science is not the barrier. Politics and funding are. Without renewed political will, experts say, hundreds of thousands of preventable infections will occur each year — and a generation of progress could be lost, according to France 24.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
25
Articles
45
Reach
70
A
AnonymousAuthor
